Kairos Pharma, Ltd. moves to expand its oncology pipeline with the proposed acquisition of two clinical-stage NSCLC assets from Celyn Therapeutics, Inc., strengthening its position in innovative cancer therapeutics.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company dedicated to advancing innovative cancer therapeutics, has announced the signing of a term sheet for the strategic acquisition of two clinical-stage oncology assets from Celyn Therapeutics, Inc., a privately held biotechnology firm backed by OrbiMed and Torrey Pines Investment. The proposed transaction would grant Kairos worldwide rights to CL-273 and CL-741, two highly differentiated assets targeting non-small cell lung cancer (NSCLC), one of the most prevalent and challenging forms of lung cancer globally.
The planned acquisition represents a significant step in Kairos Pharma’s strategy to expand its oncology pipeline with next-generation targeted therapies designed to overcome drug resistance. The two assets—CL-273, a pre-IND reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor—are intended to address critical unmet needs in patients with EGFR-mutant NSCLC and those who develop resistance driven by MET amplification or mutation.
Strengthening the Oncology Pipeline
John Yu, M.D., Chief Executive Officer of Kairos Pharma, emphasized that the acquisition would meaningfully enhance the company’s development portfolio. According to Dr. Yu, the addition of late-preclinical and Phase 1-ready compounds positions the company to compete in a multi-billion-dollar oncology market while addressing substantial unmet medical needs. He noted that resistance to EGFR-targeted therapies remains a major challenge in lung cancer treatment and that integrating highly selective inhibitors targeting both EGFR and c-MET pathways could offer a transformative therapeutic approach.
Kairos Pharma plans to leverage its established clinical consortia on the West Coast, anchored at Cedars-Sinai Medical Center in Los Angeles, to accelerate the advancement of both programs. The company believes its clinical infrastructure and expertise will enable rapid initiation and execution of Phase 1 and Phase 2 studies, pending completion of the acquisition.
Scientific Rationale for Dual Targeting
The scientific foundation behind combining a pan-EGFR inhibitor with a c-MET inhibitor in NSCLC is well supported by clinical research. MET amplification is recognized as one of the most important mechanisms of acquired resistance in EGFR-mutant NSCLC. When tumors initially respond to EGFR tyrosine kinase inhibitors (TKIs), many eventually develop compensatory signaling pathways—most notably MET activation—that restore tumor growth and survival.
By simultaneously inhibiting EGFR and MET pathways, researchers aim to overcome this compensatory signaling, deepen tumor responses, and extend progression-free survival. Clinical studies, including the SAVANNAH trial, have demonstrated that combination treatment with EGFR and MET inhibitors in EGFR-mutant, MET-amplified NSCLC patients can achieve progression-free survival of approximately seven months, representing a meaningful improvement over single-agent therapy.
Kairos Pharma believes that the pairing of CL-273 and CL-741 could establish a differentiated dual-target strategy capable of addressing both primary oncogenic drivers and resistance mechanisms. This approach may not only enhance durability of response but also reduce the emergence of MET-mediated escape clones.
Market Opportunity and Unmet Need
The global market for kinase inhibitors in oncology continues to expand rapidly. In 2025, kinase inhibitors for cancer treatment were estimated to be valued at approximately $60.7 billion, with EGFR inhibitors accounting for 32.5% of that total. The EGFR-mutated lung cancer treatment market alone is projected to reach $16.2 billion by 2026.
EGFR mutations are present in approximately 10–15% of NSCLC cases in Western populations and up to 50% in Asian populations, creating a substantial addressable patient population worldwide. Despite the availability of multiple EGFR-targeted therapies, resistance inevitably develops in many patients, limiting long-term clinical benefit.
Meanwhile, the c-MET inhibitor market is experiencing significant growth, currently valued at over $2 billion and projected to exceed $10 billion by 2030, with a compound annual growth rate surpassing 17%. MET exon 14 skipping mutations and MET amplification are recognized drivers not only in NSCLC but also in other malignancies, including gastric, liver, and renal cancers.
CL-273: A Next-Generation Pan-EGFR Inhibitor
CL-273 is an investigational, reversible, wild-type-sparing pan-EGFR small-molecule inhibitor specifically engineered for EGFR-mutant NSCLC. Developed using Celyn Therapeutics’ proprietary AI-driven drug discovery platform, the compound is designed to selectively target mutated forms of EGFR while sparing wild-type EGFR, thereby potentially reducing toxicity.
Preclinical data indicate that CL-273 maintains broad-spectrum activity against classical EGFR mutations, including Exon 19 deletions and Exon 21 L858R substitutions, as well as Exon 20 insertions, atypical variants, and resistance-associated mutations that bypass currently approved TKIs. A defining feature of CL-273 is its exceptional selectivity index. By sparing wild-type EGFR, early studies suggest a 4–5-fold wider therapeutic window compared to existing competitive inhibitors, potentially translating into improved safety and tolerability for patients.
Additionally, CL-273 has been engineered for high brain and lung permeability to address metastatic disease, including central nervous system involvement, which is common in advanced NSCLC. The compound demonstrates favorable ADME properties and has successfully completed GLP toxicology studies. The program is currently in the pre-IND stage, with first-in-human clinical trials projected to begin in 2026.
CL-741: Targeting c-MET-Driven Resistance
CL-741 is an orally available, small-molecule type IIb c-MET kinase inhibitor designed for high selectivity and broad mutation coverage. The compound exhibits potent activity across multiple c-MET resistance mutants and is being developed for advanced solid tumors driven by c-MET alterations, with a primary focus on NSCLC harboring MET exon 14 skipping mutations and MET amplification.
Given that MET amplification is one of the most common mechanisms of acquired resistance to EGFR TKIs, CL-741 is positioned to address a critical gap in current treatment strategies. By inhibiting c-MET signaling in tumors that either harbor baseline MET alterations or develop MET-driven resistance, CL-741 could restore sensitivity to EGFR-targeted therapies when used in combination.
Strategic and Clinical Implications
If successfully completed, the acquisition of CL-273 and CL-741 would enable Kairos Pharma to pursue a differentiated development strategy built around rational combination therapy. Developing the two compounds together offers a comprehensive approach to treating EGFR-mutant NSCLC patients, including those who present with baseline MET overexpression or acquire MET-mediated resistance during treatment.
The dual-target strategy aligns with emerging clinical evidence supporting combined EGFR and MET inhibition as a means to enhance response rates and extend survival outcomes. By integrating a wild-type-sparing pan-EGFR inhibitor with a selective c-MET inhibitor, Kairos aims to deepen and prolong tumor responses while potentially expanding the treatable patient population.
Nikolay Savchuk, Ph.D., CEO of Celyn Therapeutics, highlighted the strength of the collaboration, noting that Celyn’s AI-driven drug design platform enabled the discovery of a highly efficacious, wild-type-sparing EGFR inhibitor with an improved safety margin. He expressed confidence that, through partnership with Kairos Pharma and its clinical network, both CL-273 and CL-741 can be rapidly advanced toward clinical development.
As the oncology landscape continues to evolve, resistance mechanisms remain one of the greatest challenges in targeted therapy. Through this strategic asset acquisition, Kairos Pharma is positioning itself at the forefront of next-generation combination strategies aimed at overcoming resistance in EGFR-mutant and c-MET-driven lung cancers. If executed successfully, the transaction could significantly enhance the company’s competitive position in the rapidly growing targeted oncology market and potentially deliver meaningful clinical benefits to patients facing limited treatment options.
